Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC MkfnS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MYrpcohq[mm2czD0bIUhXkWJRj3pcoR2[2WmIIDyc4xq\mW{YYTpc44hd2ZiSGXWSWN{ M4W2PVE5PjJyM{iy
HUVEC MnPqT4lv[XOnIHHzd4F6 NUmzT2EycW6qaXLpeJMhXkWJRj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDWSWdHWi1{IHnuJGhWXkWFIHPlcIx{KHerdHigZY4hUUN3MDDv[kDjkLx6IH7N M3;CXVE5PjJyM{iy
MM NFHNc4ZMcW6jc3WgZZN{[Xl? MYHpcohq[mm2czDWSWdHNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKG[udEG= Ml;5NVcyPjR|M{K=
MM.1S MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWLJVI4yOTBizsznM41N NVPTeIVvcW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= NGTUbVYyPzF4NEOzNi=>
MM.1R M4iwTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MWqxNEDPxGdxbVy= MnrSbY5pcWKrdIOgUW0hS2WubDDHdo94fGh? MW[xO|E3PDN|Mh?=
RPMI M4H6dWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MY[xNEDPxGdxbVy= MlfkbY5pcWKrdIOgUW0hS2WubDDHdo94fGh? MkfSNVcyPjR|M{K=
Dox40 NX\GXHpnT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NGfWPGwyOCEQvHevcWw> M4X3O4lvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq M4fhWFE4OTZ2M{Oy
INA-6 MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MV:xNEDPxGdxbVy= MkH4bY5pcWKrdIOgUW0hS2WubDDHdo94fGh? NUjvbXhSOTdzNkSzN|I>
OPM2 M2Pxdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXWxNEDPxGdxbVy= MUnpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MVuxO|E3PDN|Mh?=
U266 MWnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M4nQdFExKM7:Zz;tUC=> NH3Rd4lqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= NF65XW8yPzF4NEOzNi=>
MM.1S Mnq2Z5l1d3SxeHnjbZR6KGG|c3H5 NGTxR|czOCEQvHevcWw> NX;3bYw1cW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> NGjKS5YyPzF4NEOzNi=>
MM.1R NGfBV4VkgXSxdH;4bYNqfHliYYPzZZk> NEfISJEzOCEQvHevcWw> MW\pcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NGLvepYyPzF4NEOzNi=>
RPMI Ml23Z5l1d3SxeHnjbZR6KGG|c3H5 NEPEXo0zOCEQvHevcWw> M3:5ZYlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= MknoNVcyPjR|M{K=
Dox40 NHHa[|VkgXSxdH;4bYNqfHliYYPzZZk> MlnkNlAh|rypL33M M4jOU4lvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NVX6VZNsOTdzNkSzN|I>
INA-6 NX\a[o1j[3m2b4TvfIlkcXS7IHHzd4F6 NXjsSm1KOjBizsznM41N M1e0W4lvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= M1PaU|E4OTZ2M{Oy
OPM2 MnHtZ5l1d3SxeHnjbZR6KGG|c3H5 M4KyT|IxKM7:Zz;tUC=> NUX1OoJCcW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> NG\BRmoyPzF4NEOzNi=>
U266 MYDjfZRwfG:6aXPpeJkh[XO|YYm= M{LN[FIxKM7:Zz;tUC=> Ml64bY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= M2nCVlE4OTZ2M{Oy
MM.1S MXvGeY5kfGmxbjDhd5NigQ>? MoTNd5VxeHKnc4Pld{BXTUeILVnu[JVk\WRiRX7kc5Rp\WyrYXygR4VtdCCScn;sbYZmemG2aX;uJIFv\CCPaXfyZZRqd25w Mn\jNVcyPjR|M{K=
MM.1R M3vuWmZ2dmO2aX;uJIF{e2G7 M2frNJN2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?= Ml3tNVcyPjR|M{K=
Dox40 NHPOboVHfW6ldHnvckBie3OjeR?= Mnnwd5VxeHKnc4Pld{BXTUeILVnu[JVk\WRiRX7kc5Rp\WyrYXygR4VtdCCScn;sbYZmemG2aX;uJIFv\CCPaXfyZZRqd25w M{jrWFE4OTZ2M{Oy
OPM2 M2fpdWZ2dmO2aX;uJIF{e2G7 NIDvNYp{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6= MUGxO|E3PDN|Mh?=
HBMEC MWHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? Mo\aglExKM7:TR?= MWjEUXNQ NY\aOnE2UUN3ME2xJO69VQ>? M4PyblIyODhzNkW2
HBMEC M4CyWmZ2dmO2aX;uJIF{e2G7 MUH+NUDPxE1? NXrPN4pOTE2VTx?= M4G4e4Fjem:pYYTld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIG\FS2ZTOiC5aYToJIRqe3K3cITpc44hd2ZiZH;3cpN1emWjbTDQUGPPuzF? MYKyNVA5OTZ3Nh?=
HBMEC MoK2SpVv[3Srb36gZZN{[Xl? Mnr5glEh|ryP NEGxVXRFVVOR Mlfp[Il{enWydIOgeIhmKFKjcz3SZYYuTVKNIIDheIh4[XlidHjyc5VocCCmZXPy[YF{\WRicHjvd5Bpd3K7bHH0[YQhVUWNMT:yJIFv\CCHUluxM|I> NX60eGdlOjFyOEG2OVY>
HBMEC MmPHSpVv[3Srb36gZZN{[Xl? MVz+NlAh|ryP M3jQfGROW09? MY\kbZNzfXC2czC1NEUhd2ZidIXi[UBnd3KvYYTpc44h[XRiMTFOwG0> MYeyNVA5OTZ3Nh?=
MDA-MB-231 MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NWPKU4R[hjFyIN88US=> MUPEUXNQ NUTvcYRKUUN3ME21JO69VQ>? NG\le5UzOTB6MU[1Oi=>
MDA-MB-231 MUXGeY5kfGmxbjDhd5NigQ>? MVmwMlUh|ryP MlzPSG1UVw>? NFnJTnRqdmirYnn0d{B1cGViRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6 Mm[2NlExQDF4NU[=
MDA-MB-231 M17CZ2Z2dmO2aX;uJIF{e2G7 NHLoVYQ2KM7:TR?= Mnr1SG1UVw>? NWLBPJVCcW6mdXPld{BiKGOnbHytZ5lkdGViYYLy[ZN1 M1rTW|IyODhzNkW2
J82 MkDZZ5l1d3SxeHnjbZR6KGG|c3H5 MkfZglExKM7:TR?= MWnEUXNQ NXGySZg{UUN3ME2yOE42PyEQvF2= NV:5ZmI4OjF3Mkm5NFA>
T24 MnjTZ5l1d3SxeHnjbZR6KGG|c3H5 MmHhglExKM7:TR?= Mo\LSG1UVw>? NEGz[XVKSzVyPUWyMlQ2KM7:TR?= MkCwNlE2Ojl7MEC=
HT1376 NWG4d3Jj[3m2b4TvfIlkcXS7IHHzd4F6 NV;iT4p[hjFyIN88US=> M4LqUWROW09? NI\5W3FKSzVyPUK4MlIyKM7:TR?= NVzkSoVTOjF3Mkm5NFA>
RT4 MmC4Z5l1d3SxeHnjbZR6KGG|c3H5 NH7OW45,OTBizszN NH23d2JFVVOR NXfxUWY6UUN3ME21MlE1KM7:TR?= NH:wT|UzOTV{OUmwNC=>
CRL1749 Mm\ZZ5l1d3SxeHnjbZR6KGG|c3H5 MVH+NVAh|ryP NWrwZ5FpTE2VTx?= MkO3TWM2OD1{Mj62PUDPxE1? NHHUNHczOTV{OUmwNC=>
HTB9 MWnjfZRwfG:6aXPpeJkh[XO|YYm= MYH+NVAh|ryP M3nidmROW09? M{jxOmlEPTB;MUGuPFQh|ryP NF;DVlUzOTV{OUmwNC=>
Sup MlvDZ5l1d3SxeHnjbZR6KGG|c3H5 NGq0UlV,OTBizszN M3\ES2ROW09? NInpd5JKSzVyPUWzMlMzKM7:TR?= MUSyNVUzQTlyMB?=
HTB3 MUPjfZRwfG:6aXPpeJkh[XO|YYm= NWnrdml6hjFyIN88US=> MVPEUXNQ M2\ocGlEPTB;MUSuNVYh|ryP NWTvbYNQOjF3Mkm5NFA>
CEC MkOzSpVv[3Srb36gZZN{[Xl? MofNglExKM7:Zz;tUC=> NYH0OpFuTE2VTx?= MXnkc5dvNXKnZ4XsZZRmeyCYRVfGJIxmfmWucx?= M2DSTlIyPjJyOEKy
RPE M1fnfWZ2dmO2aX;uJIF{e2G7 NHz6S45,OTBizsznM41N M1z5SmROW09? NIjmdplld3ewLYLl[5Vt[XSnczDWSWdHKGyndnXsdy=> MY[yNVYzODh{Mh?=
CEC MmPsSpVv[3Srb36gZZN{[Xl? NGLYe3V,PSEQvHevcWw> M{LFbGROW09? Mn;iZoxw[2u|IHXu[I91cGWuaXHsJINmdGxibXnndoF1cW:w NES0Z2ozOTZ{MEiyNi=>
5637 NFq5V3RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MYrEUXNQ MlvlTWM2OD1zNT6w5qCK|ryP NWnoXZNzOjN6OEe2NFU>
J82 M{H4SWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NXXuc3BTTE2VTx?= NUPRSXF3UUN3ME2xPE416oDLzszN NUnTPWZIOjN6OEe2NFU>
5637 MkHsRZV1d3CqYXf5JIF{e2G7 Mnu2NlAh|ryP MmHJSG1UVw>? MkD6eJJq\2encoOgeIhmKGG3dH;wbIFocWNicILvZ4V{ew>? MlvoNlM5QDd4MEW=
J82 MWTBeZRweGijZ4mgZZN{[Xl? M2\vWVIxKM7:TR?= NF60fWNFVVOR M3[5SJRzcWepZYLzJJRp\SCjdYTvdIhi\2mlIIDyc4Nme3N? NVi4cZZNOjN6OEe2NFU>
5637 NWTaeW5pTnWwY4Tpc44h[XO|YYm= NX\wT2JMOjBizszN Ml;zSG1UVw>? MlznbY5lfWOnczDsfZNwe2:vYXyt[IVx\W6mZX70JI5m[3Kxc3nz NIGwZZAzOzh6N{[wOS=>
J82 M3riTGZ2dmO2aX;uJIF{e2G7 NE\TRnEzOCEQvF2= MXLEUXNQ M4rMZolv\HWlZYOgcJl{d3OxbXHsMYRmeGWwZHXueEBv\WO{b4Ppdy=> NWH6WZNKOjN6OEe2NFU>
5637 NGTLcFhHfW6ldHnvckBie3OjeR?= MXGyNEDPxE1? M2TVNGROW09? MX;pcoR2[2W|IHz5d49{d22nIHHseIVz[XSrb36gZY5lKGmwaHnibZR{KEOEIHHjeIl3cXS7 NXL2VHViOjN6OEe2NFU>
J82 NIewVYNHfW6ldHnvckBie3OjeR?= NYnaXmJiOjBizszN M3z1b2ROW09? MoqxbY5lfWOnczDsfZNwe2:vZTDhcJRmemG2aX;uJIFv\CCrbnjpZol1eyCFQjDhZ5Rqfmm2eR?= MWeyN|g5PzZyNR?=
KATO-II NYLpRZkyT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1H5T|Uh|ryP M{XoXWROW09? MYficI9kc3NicILvcIln\XKjdHnvci=> MYqyOVI1QTV3Nx?=
OCUM-2M MXjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NVHZe2ZqPSEQvF2= MUPEUXNQ MoTyZoxw[2u|IIDyc4xq\mW{YYTpc44> NYrrUoZEOjV{NEm1OVc>
SNU-16 M1nhSWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MXG1JO69VQ>? MVjEUXNQ NHu2OW5jdG:la4OgdJJwdGmoZYLheIlwdg>? MXyyOVI1QTV3Nx?=
HSC-39 NHHUbolIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= MXS1JO69VQ>? NUnx[ppFTE2VTx?= NIP2O2xjdG:la4OgdJJwdGmoZYLheIlwdg>? MW[yOVI1QTV3Nx?=
KATO-II NYrFO3ZP[3m2b4TvfIlkcXS7IHHzd4F6 M1;Dbp4yOCEQvF2= M2nocmROW09? NVrKNpQ1UUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= MnH0NlUzPDl3NUe=
OCUM-2M NYH0WGFv[3m2b4TvfIlkcXS7IHHzd4F6 NV;NOVBRhjFyIN88US=> NH7WWG5FVVOR MlH4TWM2OD1yLkGgeI8hOi5yIN88cY9tN0x? NV[1Wlc1OjV{NEm1OVc>
SNU-16 MXPjfZRwfG:6aXPpeJkh[XO|YYm= NUHpXHdLhjFyIN88US=> MXzEUXNQ MXjJR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? MkTPNlUzPDl3NUe=
HSC-39 MmHuZ5l1d3SxeHnjbZR6KGG|c3H5 M3Xre54yOCEQvF2= MXfEUXNQ NF3LOnhKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?= M13jbVI2OjR7NUW3
NIH 3T3 MmC2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NHnSUIR,OTBizszN MWDEUXNQ M3uwZolvcGmkaYTzJINmdGxiZ4Lve5RpKGGwZDDjc4xwdnliZn;ycYF1cW:w MVOyOVI1QTV3Nx?=
KATO-III M{nxS2Z2dmO2aX;uJIF{e2G7 NEXEPG8yKM7:TR?= M4XVXGROW09? NIjsWYxqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 MlHkNlUzPDl3NUe=
OCUM-2M MmntSpVv[3Srb36gZZN{[Xl? MkLvNUDPxE1? M4X2fmROW09? NYHydnNlcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeC=> M3e3cFI2OjR7NUW3
KATO-III NWTkO4NNSXCxcITvd4l{KGG|c3H5 MV[xJO69VQ>? NUL4fYpiTE2VTx?= MYLpcoR2[2W|IHHwc5B1d3Orcx?= MWSyOVI1QTV3Nx?=
OCUM-2M MVTBdI9xfG:|aYOgZZN{[Xl? NVPsXGE1OSEQvF2= M4PvOGROW09? MnnBbY5lfWOnczDhdI9xfG:|aYO= MWeyOVI1QTV3Nx?=
KATO-III M{TZbGZ2dmO2aX;uJIF{e2G7 NFLiWYgyKM7:TR?= MYLEUXNQ MkDubY5pcWKrdIOgSmdHWjJicHjvd5Bpd3K7bHH0bY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[{Bud2ynY4Xs[ZM> MoGwNlUzPDl3NUe=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research:

[1]

+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)
Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID